Peggy Cuilliere-Dartigues

Learn More
PURPOSE Adding oxaliplatin to adjuvant 5-fluorouracil (5-FU) chemotherapy improves 3-year disease-free survival (DFS) after resection of stage III colon cancer. Several studies suggest that patients with tumors exhibiting defective mismatch repair (MMR) do not benefit from adjuvant 5-FU chemotherapy, but there are few data on 5-FU-oxaliplatin (FOLFOX)(More)
Purpose: Adding oxaliplatin to adjuvant 5-fluorouracil (5-FU) chemotherapy improves 3-year diseasefree survival (DFS) after resection of stage III colon cancer. Several studies suggest that patients with tumors exhibiting defectivemismatch repair (MMR)donot benefit fromadjuvant 5-FU chemotherapy, but there are few data on 5-FU–oxaliplatin (FOLFOX) adjuvant(More)
  • 1